, Essais cliniques portant sur les dispositifs médicaux et dispositifs médicaux de diagnostic in vitro -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

, LOI n° 2012-300 du 5 mars 2012 relative aux recherches impliquant la personne humaine, 2012.

D. L. Bhatt and C. Mehta, Adaptive Designs for Clinical Trials, N Engl J Med. 7 juill, vol.375, issue.1, pp.65-74, 2016.

M. Rosenblatt, The Large Pharmaceutical Company Perspective, N Engl J Med. 5 janv, vol.376, issue.1, pp.52-60, 2017.

B. E. Storer, Design and analysis of phase I clinical trials, Biometrics. sept, vol.45, issue.3, pp.925-962, 1989.

S. Liu, C. Cai, and J. Ning, Up-and-down designs for phase I clinical trials, Contemp Clin Trials. sept, vol.36, issue.1, pp.218-245, 2013.

E. Reiner, X. Paoletti, O. Quigley, and J. , Operating characteristics of the standard phase I clinical trial design, Comput Stat Data Anal. 28 mai, vol.30, issue.3, pp.303-318, 1999.

R. Simon, B. Freidlin, L. Rubinstein, S. G. Arbuck, J. Collins et al., Accelerated titration designs for phase I clinical trials in oncology, J Natl Cancer Inst. 6 août, vol.89, issue.15, pp.1138-1185, 1997.

J. O'quigley, M. Pepe, and L. Fisher, Continual reassessment method: a practical design for phase 1 clinical trials in cancer, Biometrics. mars, vol.46, issue.1, pp.33-48, 1990.

F. Yan, P. F. Thall, K. H. Lu, M. R. Gilbert, and Y. Yuan, Phase I-II clinical trial design: a state-ofthe-art paradigm for dose finding, Ann Oncol Off J Eur Soc Med Oncol, vol.01, issue.3, pp.694-703, 2018.

M. I. Alam, D. S. Coad, and B. Bogacka, Combined criteria for dose optimisation in early phase clinical trials, Stat Med. 27 juin, 2019.

. Sclerodermie_systemique_fr_fr_pnds,

E. Hachulla, P. Clerson, D. Launay, M. Lambert, S. Morell-dubois et al., Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study, J Rheumatol. déc, vol.34, issue.12, pp.2423-2453, 2007.

O. Kowal-bielecka, J. Fransen, J. Avouac, M. Becker, A. Kulak et al., Update of EULAR recommendations for the treatment of systemic sclerosis, Ann Rheum Dis. 1 août, vol.76, issue.8, pp.1327-1366, 2017.

G. Guyatt, A. D. Oxman, E. A. Akl, R. Kunz, G. Vist et al., GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J Clin Epidemiol. avr, vol.64, issue.4, pp.383-94, 2011.

M. Roustit, S. Blaise, and J. Cracowski, Trials and tribulations of skin iontophoresis in therapeutics, Br J Clin Pharmacol. janv, vol.77, issue.1, pp.63-71, 2014.

M. Zhao, B. Song, J. Pu, T. Wada, B. Reid et al., Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN, Nature. 27 juill, vol.442, issue.7101, pp.457-60, 2006.

S. Gohin, D. Sigaudo-roussel, A. Conjard-duplany, L. Dubourg, J. L. Saumet et al., What can current stimulation tell us about the vascular function of endogenous prostacyclin in healthy rat skin in vivo?, J Invest Dermatol. janv, vol.131, issue.1, pp.237-281, 2011.

C. Khouri, S. Kotzki, M. Roustit, S. Blaise, F. Gueyffier et al., Hierarchical evaluation of electrical stimulation protocols for chronic wound healing: An effect size metaanalysis. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc, vol.25, pp.883-91, 2017.

H. M. Peshavariya, G. Liu, C. Chang, F. Jiang, E. C. Chan et al., Prostacyclin signaling boosts NADPH oxidase 4 in the endothelium promoting cytoprotection and angiogenesis, Antioxid Redox Signal. 10 juin, vol.20, issue.17, pp.2710-2735, 2014.

C. Francès, Y. Allanore, J. Cabane, P. Carpentier, C. Dumontier et al.,

, Presse Medicale Paris Fr, vol.37, issue.2, pp.271-85, 1983.

S. Blaise, M. Roustit, M. Hellmann, C. Millet, and J. Cracowski, Cathodal iontophoresis of treprostinil induces a sustained increase in cutaneous blood flux in healthy volunteers, J Clin Pharmacol. janv, vol.53, issue.1, pp.58-66, 2013.

S. Kotzki, M. Roustit, C. Arnaud, D. Godin-ribuot, and J. Cracowski, Effect of continuous vs pulsed iontophoresis of treprostinil on skin blood flow, Eur J Pharm Sci Off J Eur Fed Pharm Sci. 25 mai, vol.72, pp.21-27, 2015.

S. Blaise, M. Roustit, C. Millet, C. Ribuot, J. Boutonnat et al., Cathodal iontophoresis of treprostinil and iloprost induces a sustained increase in cutaneous flux in rats, Br J Pharmacol. févr, vol.162, issue.3, pp.557-65, 2011.

M. Roustit, F. Gaillard-bigot, S. Blaise, F. Stanke-labesque, C. Cracowski et al., Cutaneous iontophoresis of treprostinil in systemic sclerosis: a proof-of-concept study, Clin Pharmacol Ther. avr, vol.95, issue.4, pp.439-484, 2014.

M. Hellmann, M. Roustit, F. Gaillard-bigot, and J. Cracowski, Cutaneous iontophoresis of treprostinil, a prostacyclin analog, increases microvascular blood flux in diabetic malleolus area, Eur J Pharmacol. 5 juill, vol.758, pp.123-131, 2015.

A. R. Tonelli, M. K. Ahmed, L. Alkukhun, F. Cikach, K. Aulak et al., Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension, Am J Respir Crit Care Med, vol.192, issue.8, pp.1014-1020, 2015.

F. Gaillard-bigot, M. Roustit, S. Blaise, C. Cracowski, C. Seinturier et al.,

, Treprostinil Iontophoresis Improves Digital Blood Flow during Local Cooling in Systemic Sclerosis. Microcirc N Y N, vol.23, pp.266-70, 1994.

F. Gaillard-bigot, M. Roustit, J. Jourdil, F. Stanke-labesque, and J. Cracowski, Vascular Effects of Treprostinil Cutaneous Iontophoresis on the Leg, Finger, and Foot, J Clin Pharmacol, vol.57, issue.9, pp.1215-1235, 2017.

J. Fransen and M. Inanc, EULAR Textbook on Systemic Sclerosis, vol.369, 2013.

M. Trojanowska, Cellular and molecular aspects of vascular dysfunction in systemic sclerosis, Nat Rev Rheumatol, vol.6, issue.8, pp.453-60, 2010.

M. Hughes and A. L. Herrick, Digital ulcers in systemic sclerosis, Rheumatology. janv, vol.56, issue.1, pp.14-25, 2017.

. Hoogen-f-van-den, D. Khanna, J. Fransen, S. R. Johnson, M. Baron et al., 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative, Ann Rheum Dis. 11 janv, vol.72, issue.11, pp.1747-55, 2013.

M. Baron, L. Chung, G. Gyger, L. Hummers, D. Khanna et al., Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis, Clin Rheumatol. févr, vol.33, issue.2, pp.207-221, 2014.

, Décision du 5 novembre 2007 relative aux bonnes pratiques de préparation. 37. CTCAE Files

Y. N. Disponible-sur-;-kalia, A. Naik, J. Garrison, and R. H. Guy, Iontophoretic drug delivery, Adv Drug Deliv Rev. 27 mars, vol.56, issue.5, pp.619-58, 2004.

K. Naik-null, G. Null, and . Null, Transdermal drug delivery: overcoming the skin's barrier function, Pharm Sci Technol Today. 1 sept, vol.3, issue.9, pp.318-344, 2000.

K. A. Holbrook and G. F. Odland, Regional differences in the thickness (cell layers) of the human stratum corneum: an ultrastructural analysis, J Invest Dermatol. avr, vol.62, issue.4, pp.415-437, 1974.

T. Yoshiike, Y. Aikawa, J. Sindhvananda, H. Suto, K. Nishimura et al., Skin barrier defect in atopic dermatitis: increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline, J Dermatol Sci. avr, vol.5, issue.2, pp.92-98, 1993.

V. Kumar and A. K. Banga, Modulated iontophoretic delivery of small and large molecules through microchannels, Int J Pharm. 15 sept, vol.434, issue.1-2, pp.106-120, 2012.

E. Tesselaar, J. Henricson, S. Jonsson, and F. Sjöberg, A Time-Response Model for Analysis of Drug Transport and Blood Flow Response during Iontophoresis of Acetylcholine and Sodium Nitroprusside, J Vasc Res, vol.46, issue.4, pp.270-277, 2009.

J. Hiremath, S. Thanikachalam, K. Parikh, S. Shanmugasundaram, S. Bangera et al., Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial, J Heart Lung Transplant Off Publ Int Soc Heart Transplant. févr, vol.29, issue.2, pp.137-186, 2010.

G. Simonneau, R. J. Barst, N. Galie, R. Naeije, S. Rich et al., Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial, Am J Respir Crit Care Med. 15 mars, vol.165, issue.6, pp.800-804, 2002.

L. Chung and D. Fiorentino, A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis, J Am Acad Dermatol. mai, vol.54, issue.5, pp.880-882, 2006.

R. Stratton, X. Shiwen, G. Martini, A. Holmes, A. Leask et al., Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients, J Clin Invest. juill, vol.108, issue.2, pp.241-50, 2001.

. Appendix_figure_2, A: Mean arterial pressure (mmHg) following iontophoresis (min) at each study visit for stage 2 patients. B: Evolution of the cutaneous vascular conductance at each visit for stage 2 patients C: Evolution of the cutaneous temperature (°C) at each study visit for stage 2 patients

, Appendix_Table_2 : Iontophoresis and follow-up characteristics of step 2 patients * The duration of follow-up was shortened at the patient's request